Binding of fullerenes to amyloid beta fibrils: size matters.

Binding affinity of fullerenes C20, C36, C60, C70 and C84 for amyloid beta fibrils is studied by docking and all-atom molecular dynamics simulations with the Amber force field and water model TIP3P. Using the molecular mechanic-Poisson Boltzmann surface area method one can demonstrate that the binding free energy linearly decreases with the number of carbon atoms of fullerene, i.e. the larger is the fullerene size, the higher is the binding affinity. Overall, fullerenes bind to Aβ9-40 fibrils stronger than to Aβ17-42. The number of water molecules trapped in the interior of 12Aβ9-40 fibrils was found to be lower than inside pentamer 5Aβ17-42. C60 destroys Aβ17-42 fibril structure to a greater extent compared to other fullerenes. Our study revealed that the van der Waals interaction dominates over the electrostatic interaction and non-polar residues of amyloid beta peptides play the significant role in interaction with fullerenes providing novel insight into the development of drug candidates against Alzheimer's disease.

[1]  E. Nakamura,et al.  siRNA delivery targeting to the lung via agglutination-induced accumulation and clearance of cationic tetraamino fullerene , 2014, Scientific Reports.

[2]  Son Tung Ngo,et al.  Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Aβ40 and Aβ42. , 2013, ACS chemical neuroscience.

[3]  Charles D. Schwieters,et al.  Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue , 2013, Cell.

[4]  Katsuhiko Ariga,et al.  Fullerene nanoarchitectonics: from zero to higher dimensions. , 2013, Chemistry, an Asian journal.

[5]  R. Mezzenga,et al.  The interplay between carbon nanomaterials and amyloid fibrils in bio-nanotechnology. , 2013, Nanoscale.

[6]  Ying Liu,et al.  Biosafety and bioapplication of nanomaterials by designing protein-nanoparticle interactions. , 2013, Small.

[7]  Son Tung Ngo,et al.  Top-leads from natural products for treatment of Alzheimer's disease: docking and molecular dynamics study , 2013 .

[8]  Katsuhiko Ariga,et al.  Alcohol-induced decomposition of Olmstead's crystalline Ag(I)-fullerene heteronanostructure yields 'bucky cubes'† , 2013 .

[9]  Son Tung Ngo,et al.  Curcumin binds to Aβ1-40 peptides and fibrils stronger than ibuprofen and naproxen. , 2012, The journal of physical chemistry. B.

[10]  Man Hoang Viet,et al.  Amyloid peptide Aβ40 inhibits aggregation of Aβ42: evidence from molecular dynamics simulations. , 2012, The Journal of chemical physics.

[11]  S. Andujar,et al.  Amyloid-β fibril disruption by C60-molecular guidance for rational drug design. , 2012, Physical chemistry chemical physics : PCCP.

[12]  H. Scheidt,et al.  Dynamics of Amyloid β Fibrils Revealed by Solid-state NMR* , 2011, The Journal of Biological Chemistry.

[13]  I. Bertini,et al.  A new structural model of Aβ40 fibrils. , 2011, Journal of the American Chemical Society.

[14]  Mai Suan Li,et al.  Study of Tamiflu Sensitivity to Variants of A/H5N1 Virus Using Different Force Fields , 2011, J. Chem. Inf. Model..

[15]  Z. Podlubnaya,et al.  Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity. , 2011, Organic and biomolecular chemistry.

[16]  John E Straub,et al.  Role of water in protein aggregation and amyloid polymorphism. , 2011, Accounts of chemical research.

[17]  Son Tung Ngo,et al.  Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity. , 2011, The journal of physical chemistry. B.

[18]  N. K. Jain,et al.  Pulmonary toxicity of carbon nanotubes: a systematic report. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[19]  H. Scheraga,et al.  Dry amyloid fibril assembly in a yeast prion peptide is mediated by long-lived structures containing water wires , 2010, Proceedings of the National Academy of Sciences.

[20]  G. Bitan,et al.  Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments. , 2010, Biochemistry.

[21]  V. Romanova,et al.  [Effect of nitroderivatives of fullerene C60 on amyloid fibrils of Abeta(1-42) peptide of the brain and muscle X-protein]. , 2010, Biofizika.

[22]  Tracy O'Connor,et al.  Protein aggregation diseases: pathogenicity and therapeutic perspectives , 2010, Nature Reviews Drug Discovery.

[23]  R. Hochstrasser,et al.  2D IR provides evidence for mobile water molecules in β-amyloid fibrils , 2009, Proceedings of the National Academy of Sciences.

[24]  H. Mihara,et al.  RNA aptamers selected against amyloid beta-peptide (Abeta) inhibit the aggregation of Abeta. , 2009, Molecular bioSystems.

[25]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[26]  Joan-Emma Shea,et al.  The structure of Abeta42 C-terminal fragments probed by a combined experimental and theoretical study. , 2009, Journal of molecular biology.

[27]  P. Troshin,et al.  [Effect of fullerenes C60 on the amyloids of X-protein]. , 2009, Biofizika.

[28]  JoAnne McLaurin,et al.  Small molecule inhibitors of Aβ‐aggregation and neurotoxicity , 2009 .

[29]  J. Straub,et al.  Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Abeta peptides with implications for rates of fibril formation. , 2009, The journal of physical chemistry. B.

[30]  Richard D. Leapman,et al.  Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils , 2008, Proceedings of the National Academy of Sciences.

[31]  D. Teplow,et al.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. , 2008, Current pharmaceutical design.

[32]  B. Berne,et al.  Role of water in mediating the assembly of Alzheimer amyloid-beta Abeta16-22 protofilaments. , 2008, Journal of the American Chemical Society.

[33]  S. Chierici,et al.  A Multimeric Quinacrine Conjugate as a Potential Inhibitor of Alzheimer's β‐Amyloid Fibril Formation , 2008, Chembiochem : a European journal of chemical biology.

[34]  J. McLaurin,et al.  Modulation of amyloid‐β aggregation and toxicity by inosose stereoisomers , 2008, The FEBS journal.

[35]  E. Kosenko,et al.  Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. , 2007, Journal of nanoscience and nanotechnology.

[36]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[37]  J. Gestwicki,et al.  Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro* , 2006, Journal of Biological Chemistry.

[38]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[39]  Shinobu Ito,et al.  Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. , 2006, Toxicology.

[40]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[41]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[42]  R. Tycko,et al.  Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. , 2006, Biochemistry.

[43]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[44]  R. Riek,et al.  3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .

[45]  Stephen R. Wilson,et al.  [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. , 2005, Nano letters.

[46]  Gerhard Hummer,et al.  Molecular dynamics simulations of Alzheimer's β-amyloid protofilaments , 2005 .

[47]  R. Tycko,et al.  Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. , 2005, Biochemistry.

[48]  M. Citron,et al.  Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[49]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[50]  B. Brooks,et al.  Self-guided Langevin dynamics simulation method , 2003 .

[51]  E. Nakamura,et al.  Functionalized fullerenes in water. The first 10 years of their chemistry, biology, and nanoscience. , 2003, Accounts of chemical research.

[52]  Minyung Lee,et al.  Fullerene inhibits β-amyloid peptide aggregation , 2003 .

[53]  A. Bush.  Metal complexing agents as therapies for Alzheimer’s disease , 2002, Neurobiology of Aging.

[54]  R. Nussinov,et al.  Stabilities and conformations of Alzheimer's β-amyloid peptide oligomers (Aβ16–22, Aβ16–35, and Aβ10–35): Sequence effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[56]  C. Soto,et al.  Beta‐sheet breaker strategy for the treatment of Alzheimer's disease , 2002 .

[57]  I. Grundke‐Iqbal,et al.  Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Butterfield,et al.  Role of spermine in amyloid β‐peptide‐associated free radical‐induced neurotoxicity , 2001, Journal of neuroscience research.

[59]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[60]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[61]  T. Wight,et al.  Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability , 1997 .

[62]  C. Soto,et al.  Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. , 1996, Biochemical and biophysical research communications.

[63]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[64]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[65]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[66]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[67]  Hans-Joachim Böhm,et al.  The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[68]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[69]  K. Dill.  Dominant forces in protein folding. , 1990, Biochemistry.

[70]  S. C. O'brien,et al.  C60: Buckminsterfullerene , 1985, Nature.

[71]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[72]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[73]  R. Hockney,et al.  Quiet high resolution computer models of a plasma , 1974 .

[74]  G. Glenner,et al.  X-RAY DIFFRACTION STUDIES ON AMYLOID FILAMENTS , 1968, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[75]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[76]  F. Moussa,et al.  Toxicity studies of fullerenes and derivatives. , 2007, Advances in experimental medicine and biology.

[77]  R. Leapman,et al.  A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  R. Céolin,et al.  Early effects of C60 Administration in Swiss Mice: A Preliminary Account for In Vivo C60 Toxicity. , 1996 .

[79]  L. Svennerholm,et al.  Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease. , 1994, Life sciences.

[80]  D. Selkoe,et al.  X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.